[go: up one dir, main page]

US5183657A - Antibodies for use in antilymphocyte antibody therapy - Google Patents

Antibodies for use in antilymphocyte antibody therapy Download PDF

Info

Publication number
US5183657A
US5183657A US07/881,317 US88131792A US5183657A US 5183657 A US5183657 A US 5183657A US 88131792 A US88131792 A US 88131792A US 5183657 A US5183657 A US 5183657A
Authority
US
United States
Prior art keywords
antibody
antilymphocyte
antibodies
necrosis factor
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US07/881,317
Inventor
Wim Buurman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech R&D Ltd
Original Assignee
Celltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888805792A external-priority patent/GB8805792D0/en
Application filed by Celltech Ltd filed Critical Celltech Ltd
Priority to US07/881,317 priority Critical patent/US5183657A/en
Application granted granted Critical
Publication of US5183657A publication Critical patent/US5183657A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Definitions

  • This invention relates to antibodies against human alpha ( ⁇ )-tumour necrosis factor for use in antilymphocyte antibody therapy, to therapeutic compositions containing an antibody against human ⁇ -tumour necrosis factor and an antilymphocyte antibody, and to recombinant antibodies against human ⁇ -tumour necrosis factor.
  • Antilymphocyte antibody therapy has become a recognised clinical technique for use when it is desired to supplement or modify the normal immune response in humans.
  • the intravenous administration of polyclonal rabbit or horse antilymphocyte antibodies is an effective treatment for acute kidney allograft rejection.
  • monoclonal antilymphocyte antibodies such as Orthoclone OKT3, have been used for this purpose.
  • ⁇ -TNF ⁇ -tumour necrosis factor
  • an antibody against human ⁇ -tumour necrosis factor for use in the prevention or treatment of shock-related conditions arising from antilymphocyte antibody therapy.
  • antilymphocyte antibody therapy is especially to be understood to mean the use of an antilymphocyte antibody in the prophylaxis or treatment of immunoregulatory disorders in which rejection of self or non-self tissue occurs, for example in autoimmune diseases such as thyroiditis or rheumatoid arthritis, or, in particular, in a rejection episode following an organ or tissue transplant.
  • the shock-related conditions which may arise from antilymphocyte antibody therapy and which may be prevented or treated according to the present invention may be any physiological conditions which are generally associated with a degree of circulatory collapse.
  • Particular conditions include, for example, cardiac conditions such as tachycardia and angina, e.g. angina pectoris; pulmonary conditions such as bronchospasm; musculo-skeletal conditions, for example joint pains such as arthralgia; and general metabolic disorders such as oedema, e.g. pulmonary oedema, and abnormal body temperatures.
  • anti-TNF ⁇ antibodies The antibodies against human ⁇ -tumour necrosis factor (hereinafter referred to as anti-TNF ⁇ antibodies) for use according to the invention may in general belong to any immunoglobulin class.
  • the anti-TNF ⁇ antibody may be an immunoglobulin G or immunoglobulin M antibody.
  • the anti-TNF ⁇ antibody may be of animal, for example mammalian origin and may be for example of murine, rat or human origin.
  • the antibody may be a whole immunoglobulin, or a fragment thereof, for example a fragment derived by proteolytic cleavage of a whole antibody, such as F(ab') 2 , Fab' or Fab fragments, or fragments obtained by recombinant DNA techniques, for example Fv fragments (as described in International Patent Application No. PCT/GB 88/00747).
  • the anti-TNF ⁇ antibody may be polyspecific but is preferably monospecific for human ⁇ -TNF.
  • the antibodies may be polyclonal or monoclonal antibodies.
  • Particularly useful antibodies for use according to the invention include recombinant anti-TNF ⁇ antibodies and fragments thereof, i.e. anti-TNF ⁇ antibodies or fragments which have been produced using recombinant DNA techniques. Such recombinant anti-TNF ⁇ antibodies are novel compounds and form another aspect of the invention.
  • Especially useful recombinant antibodies include, (1) those having an antigen binding site at least part of which is derived from a different antibody, for example those in which the hypervariable or complementarity determining regions of one antibody have been grafted into the variable framework regions of a second, different antibody (as described in European Patent Specification No. 239400); (2) recombinant antibodies or fragments wherein non-Fv sequences have been substituted by non-Fv sequences from other, different antibodies (as described in European Patent Specifications Nos.
  • the anti-TNF ⁇ antibodies may be prepared using well-known immunological techniques employing ⁇ -TNF as antigen.
  • any suitable host may be injected with ⁇ -TNF and the serum collected to yield the desired polyclonal anti-TNF ⁇ antibody after appropriate purification and/or concentration, (for example by affinity chromatography using immobilised ⁇ -TNF as the affinity medium).
  • splenocytes or lymphocytes may be recovered from the ⁇ -TNF-injected host and immortalised using for example the method of Kohler et al., Eur. J. Immunol. 6, 511, (1976), the resulting cells being segregated to obtain a single genetic line producing monoclonal anti-TNF ⁇ antibodies in accordance with conventional practice.
  • Antibody fragments may be produced using conventional techniques, for example by enzymatic digestion of whole antibodies e.g. with pepsin [Parham, J. Immunol., 131, 2895, (1983)] or papain [Lamoyi and Nisonoff, J. Immunol. Meth., 56, 235, (1983)]. Where it is desired to produce recombinant anti-TNF ⁇ antibodies these may be produced using for example the general methods described in the above-mentioned patent specifications.
  • anti-TNF ⁇ antibodies may in general be administered in an appropriate form and amount at any suitable time before or during the therapy and, where necessary, after the therapy has finished.
  • the anti-TNF ⁇ antibodies may be administered seperately or together with antilymphocyte antibodies.
  • each component for use in association with one another in antilymphocyte antibody therapy, said system comprising (1) a first component that is an anti-TNF ⁇ antibody, and (2) a second component that is an antilymphocyte antibody.
  • anti-TNF ⁇ and antilymphocyte antibodies are administered separately, each may be formulated according to conventional practice.
  • a pharmaceutical composition comprising an anti-TNF ⁇ antibody together with one or more pharmaceutically acceptable carriers, excipients or diluents for use in the prevention or treatment of shock conditions arising from antilymphocyte antibody therapy.
  • compositions according to this aspect of the invention may contain other active ingredients.
  • compositions which comprises an anti-TNF ⁇ antibody and an antilymphocyte antibody in admixture with one or more pharmaceutically acceptable carriers, excipients or diluents.
  • composition which comprises an anti-TNF ⁇ antibody, and an antilymphocyte antibody in admixture with one or more pharmaceutically acceptable carriers, excipients or diluents, for use in antilymphocyte antibody therapy.
  • a pharmaceutical composition for use in the prevention or treatment of shock conditions arising from antilymphocyte antibody therapy which comprises admixing an anti-TNF ⁇ antibody and one or more pharmaceutically acceptable carriers, excipients or diluents.
  • the antilymphocyte antibody may be for example a polyclonal rabbit or horse antilymphocyte antibody, or a monoclonal antilymphocyte antibody such as Orthoclone OKT3.
  • Such antibodies are readily available from known sources.
  • compositions may take any suitable form for administration, and in particular will be in a form suitable for parenteral administration e.g. by injection or infusion, for example by bolus injection or continuous infusion.
  • Compositions for injection or infusion may take such forms as suspensions, solutions or emulsions of the antibody in oily or aqueous vehicles, and, may contain formulatory agents such as suspending, stabilising and/or dispensing agents.
  • the composition may be in a dry form, for reconstitution before use with an appropriate sterile liquid.
  • the dose at which the anti-TNF ⁇ antibody will be administered will depend on the nature of the antilymphocyte antibody therapy in use and whether the anti-TNF ⁇ antibody is being used prophylactically or to treat an existing shock-related condition arising from antilymphocyte antibody therapy.
  • the anti-TNF ⁇ antibody may be administered by infusion to a 70 kg man, usually at a total dose in the range 20-500 mg, over for example 2-3 days or for as long as the shock condition arising from the antilymphocyte antibody therapy persists.
  • the antilymphocyte antibody may be infused at generally accepted doses depending on the antibody in use, for example with Orthoclone OKT3 at a dose of 5 mg/day for 10-14 days in a 70 kg man.
  • a method of treatment of a human subject suffering from an immunoregulatory disorder which comprises administering effective amounts of an anti-TNF ⁇ antibody and an antilymphocyte antibody in association to the human subject.
  • Immunoregulatory disorders include, for example, those described above.
  • a method of treatment of a human subject suffering from a shock condition arising from antilymphocyte antibody therapy which comprises administering an effective amount of an effective amount of an anti-TNF ⁇ antibody to the human subject.
  • ATG treatment consisted of intravenous administration of 100-300 mg ATG together with 50 mg prednisolone in 500 ml saline, infused over a 8-hr period. All patients received 4 mg of the antihistamine chlorepheniraminemaleate orally 1/2 hr before start of the infusion.
  • EDTA-anticoagulated 5 ml blood samples were drawn from an intravenous line inserted in the arm opposite the one in which ATG was infused. Blood samples were immediately centrifuged and aliquots of plasma were stored at -70° C. for measurement of TNF concentration. During treatment patient temperature and blood pressure were monitored and the occurrence of other side effects of the treatment was registered.
  • Plasma TNF concentrations were determined with a TNF-specific ELISA using monoclonal and polyclonal anti-TNF antibodies.
  • Monoclonal antibodies were derived from anti-TNF secreting hybridomas obtained by a standard cell fusion procedure. Two different monoclonal antibodies were coated overnight at 4° C. in a flatbottom microtiter plate (Greiner, Nurtingen, FRG) at a final concentration of 5 ug Ig/ml. Plates were blocked with 1% (w/v) bovine serum albumin. Samples to be tested for TNF concentration were added to the wells and incubated for 11/2 hrs. at room temperature. A standard titration curve was obtained by making serial dilutions of a known sample of recombinant TNF.
  • the amount of TNF bound to the wells was quantitated by sequential incubation with a 1:2000 dilution of rabbit immune serum and a 1:5000 dilution of peroxidase conjugated goat anti-rabbit antibody (Jackson, West Grove, PA; antibody not crossreactive with human serum proteins), followed by adding substrate (o-phenylenediamine: Sigma, St. Louis, MO) to the wells.
  • the colour reaction was stopped with 0.1M H 2 SO 4 and absorption of light at 495 nm was measured with a microelisa autoreader (Flow, Irvine, UK).
  • the lower detection limit of ELISA ranged between 5-10 pg/ml in plasma.
  • TNF specific values were obtained by subtracting background absorptions due to non-TNF plasma proteins cross-linking in the ELISA, measured in the absence of either the monoclonal anti-TNF antibodies coated on the bottom of the ELISA plate or the second, rabbit anti-TNF antibodies.
  • PBMC Peripheral blood mononuclear cells
  • PBMC and monocytes were cultured in RPMI 1640 (Gibco, Paisley, Scotland) supplemented with 10% heat-inactivated (56° C., 20 min.) foetal calf serum (Boehringer, Mannheim, FRG) and 100 IU/ml penicillin and 100 ug/ml streptomycin (Flow, Irvine, UK).
  • PBMC and monocytes were cultured in cluster wells (24-well plates, Greiner); In each well 2.5 ⁇ 10 8 PBMC and monocytes obtained after adherence of 2.5 ⁇ 10 8 T lymphocyte depleted PBMC per well were cultured in 600 ul medium.
  • Table I gives the relevant data on all 7 patients. Maxium plasma TNF concentrations in these patients ranged between 111 and 731 pg/ml on the first day of treatment. On the second day of treatment, when side effects of the ATG infusion were considerably less, maximum TNF levels were much lower, i.e. between 0 and 55 pg/ml.
  • ATG or OKT3 was added at different concentrations to cultures of peripheral blood mononuclear cells (PBMC) and after a 6 hour culture period, TNF concentration in the supernatant was determined. Both ATG and OKT3 induced in a dose-related manner the release of TNF by PBMC in vitro.
  • OKT3 which is a T-cell mitogen, also induced T-lymphocyte proliferation.
  • ATG induced TNF secretion was not accompanied by T-lymphocyte proliferation, indicating that proliferation of T-lymphocytes is not a necessary prerequisite for TNF production in these cultures.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PCT No. PCT/GB89/00254 Sec. 371 Date Oct. 22, 1990 Sec. 102(e) Date Oct. 22, 1990 PCT Filed Mar. 13, 1989 PCT Pub. No. WO89/08460 PCT Pub. Date Sep. 21, 1989.The use of antibodies against human alpha tumor necrosis factor in antilymphocyte antibody therapy is described. The anti-human alpha tumor necrosis factor antibodies may be used to prevent or treat shock-related conditions arising from antilymphocyte antibody therapy. Also described are compositions containing anti-human alpha tumor necrosis factor antibodies and antilymphocyte antibodies, as well as recombinant anti-human alpha tumor necrosis factor antibodies.

Description

This is a continuation of application Ser. No. 07/585,065, filed Oct. 22, 1990, now abandoned.
FIELD OF THE INVENTION
This invention relates to antibodies against human alpha (α)-tumour necrosis factor for use in antilymphocyte antibody therapy, to therapeutic compositions containing an antibody against human α-tumour necrosis factor and an antilymphocyte antibody, and to recombinant antibodies against human α-tumour necrosis factor.
BACKGROUND TO THE INVENTION
Antilymphocyte antibody therapy has become a recognised clinical technique for use when it is desired to supplement or modify the normal immune response in humans. Thus, for example, the intravenous administration of polyclonal rabbit or horse antilymphocyte antibodies is an effective treatment for acute kidney allograft rejection. More recently, monoclonal antilymphocyte antibodies, such as Orthoclone OKT3, have been used for this purpose.
Despite the effectiveness of antilymphocyte antibody therapy, treatment has been hindered in many cases by the occurence of shock-related side effects, making it necessary to temporarily discontinue the antibody infusion. Side effects include fever and chills, arthralgias, nausea and vomiting, tachycardia, angina pectoris, dyspnoea due to bronchospasm, and, in the case of OKT3 infusion, pulmonary oedema. In addition to the discomfort these side effects can cause, the severity of some of the effects precludes the use of antilymphocyte antibody therapy in some patients, for example people with pulmonary or cardiac disease.
We have now found that patients who are undergoing antilymphocyte antibody therapy, and who are also experiencing shock-related side effects, have surprisingly high plasma levels of α-tumour necrosis factor (α-TNF). We have used this to develop means to control shock-related conditions arising from antilymphocyte antibody therapy.
SUMMARY OF THE INVENTION
Thus, according to one aspect of the invention we provide an antibody against human α-tumour necrosis factor for use in the prevention or treatment of shock-related conditions arising from antilymphocyte antibody therapy.
The term antilymphocyte antibody therapy as used herein is especially to be understood to mean the use of an antilymphocyte antibody in the prophylaxis or treatment of immunoregulatory disorders in which rejection of self or non-self tissue occurs, for example in autoimmune diseases such as thyroiditis or rheumatoid arthritis, or, in particular, in a rejection episode following an organ or tissue transplant.
The shock-related conditions which may arise from antilymphocyte antibody therapy and which may be prevented or treated according to the present invention may be any physiological conditions which are generally associated with a degree of circulatory collapse. Particular conditions include, for example, cardiac conditions such as tachycardia and angina, e.g. angina pectoris; pulmonary conditions such as bronchospasm; musculo-skeletal conditions, for example joint pains such as arthralgia; and general metabolic disorders such as oedema, e.g. pulmonary oedema, and abnormal body temperatures.
The antibodies against human α-tumour necrosis factor (hereinafter referred to as anti-TNFα antibodies) for use according to the invention may in general belong to any immunoglobulin class. Thus for example the anti-TNFα antibody may be an immunoglobulin G or immunoglobulin M antibody.
The anti-TNFα antibody may be of animal, for example mammalian origin and may be for example of murine, rat or human origin. The antibody may be a whole immunoglobulin, or a fragment thereof, for example a fragment derived by proteolytic cleavage of a whole antibody, such as F(ab')2, Fab' or Fab fragments, or fragments obtained by recombinant DNA techniques, for example Fv fragments (as described in International Patent Application No. PCT/GB 88/00747).
The anti-TNFα antibody may be polyspecific but is preferably monospecific for human α-TNF. The antibodies may be polyclonal or monoclonal antibodies. Particularly useful antibodies for use according to the invention include recombinant anti-TNFα antibodies and fragments thereof, i.e. anti-TNFα antibodies or fragments which have been produced using recombinant DNA techniques. Such recombinant anti-TNFα antibodies are novel compounds and form another aspect of the invention.
Especially useful recombinant antibodies include, (1) those having an antigen binding site at least part of which is derived from a different antibody, for example those in which the hypervariable or complementarity determining regions of one antibody have been grafted into the variable framework regions of a second, different antibody (as described in European Patent Specification No. 239400); (2) recombinant antibodies or fragments wherein non-Fv sequences have been substituted by non-Fv sequences from other, different antibodies (as described in European Patent Specifications Nos. 171496, 173494 and 194276); or (3) recombinant antibodies or fragments possessing substantially the structure of a natural immunoglobulin but wherein the hinge region has a different number of cysteine residues from that found in the natural immunoglobulin, or wherein one or more cysteine residues in a surface pocket of the recombinant antibody or fragment is in the place of another amino acid residue present in the natural immunoglobulin (as described in International patent Applications Nos. PCT/GB 88/00730 and PCT/GB 88/00729 respectively).
The anti-TNFα antibodies may be prepared using well-known immunological techniques employing α-TNF as antigen. Thus, for example, any suitable host may be injected with α-TNF and the serum collected to yield the desired polyclonal anti-TNFα antibody after appropriate purification and/or concentration, (for example by affinity chromatography using immobilised α-TNF as the affinity medium). Alternatively, splenocytes or lymphocytes may be recovered from the α-TNF-injected host and immortalised using for example the method of Kohler et al., Eur. J. Immunol. 6, 511, (1976), the resulting cells being segregated to obtain a single genetic line producing monoclonal anti-TNFα antibodies in accordance with conventional practice. Antibody fragments may be produced using conventional techniques, for example by enzymatic digestion of whole antibodies e.g. with pepsin [Parham, J. Immunol., 131, 2895, (1983)] or papain [Lamoyi and Nisonoff, J. Immunol. Meth., 56, 235, (1983)]. Where it is desired to produce recombinant anti-TNFα antibodies these may be produced using for example the general methods described in the above-mentioned patent specifications.
In order to prevent or treat shock-related conditions arising from antilymphocyte antibody therapy, anti-TNFα antibodies may in general be administered in an appropriate form and amount at any suitable time before or during the therapy and, where necessary, after the therapy has finished. The anti-TNFα antibodies may be administered seperately or together with antilymphocyte antibodies.
Thus according to a further aspect of the invention we provide a two component system, each component for use in association with one another in antilymphocyte antibody therapy, said system comprising (1) a first component that is an anti-TNFα antibody, and (2) a second component that is an antilymphocyte antibody.
Where the anti-TNFα and antilymphocyte antibodies are administered separately, each may be formulated according to conventional practice. Thus, according to a further aspect of the invention, we provide a pharmaceutical composition comprising an anti-TNFα antibody together with one or more pharmaceutically acceptable carriers, excipients or diluents for use in the prevention or treatment of shock conditions arising from antilymphocyte antibody therapy.
The compositions according to this aspect of the invention may contain other active ingredients.
Where it is desired to administer the anti-TNFα and antilymphocyte antibody together, these may be conveniently formulated in the same composition. Thus according to a further aspect of the invention we provide a pharmaceutical composition which comprises an anti-TNFα antibody and an antilymphocyte antibody in admixture with one or more pharmaceutically acceptable carriers, excipients or diluents.
In yet a further aspect of the invention we provide a pharmaceutical composition which comprises an anti-TNFα antibody, and an antilymphocyte antibody in admixture with one or more pharmaceutically acceptable carriers, excipients or diluents, for use in antilymphocyte antibody therapy.
In a still further aspect of the invention, we provide a method for the manufacture of a pharmaceutical composition for use in the prevention or treatment of shock conditions arising from antilymphocyte antibody therapy which comprises admixing an anti-TNFα antibody and one or more pharmaceutically acceptable carriers, excipients or diluents.
In the compositions according to the invention the antilymphocyte antibody may be for example a polyclonal rabbit or horse antilymphocyte antibody, or a monoclonal antilymphocyte antibody such as Orthoclone OKT3. Such antibodies are readily available from known sources.
The compositions may take any suitable form for administration, and in particular will be in a form suitable for parenteral administration e.g. by injection or infusion, for example by bolus injection or continuous infusion. Compositions for injection or infusion may take such forms as suspensions, solutions or emulsions of the antibody in oily or aqueous vehicles, and, may contain formulatory agents such as suspending, stabilising and/or dispensing agents. Alternatively, the composition may be in a dry form, for reconstitution before use with an appropriate sterile liquid.
The dose at which the anti-TNFα antibody will be administered will depend on the nature of the antilymphocyte antibody therapy in use and whether the anti-TNFα antibody is being used prophylactically or to treat an existing shock-related condition arising from antilymphocyte antibody therapy. Thus, for example, the anti-TNFα antibody may be administered by infusion to a 70 kg man, usually at a total dose in the range 20-500 mg, over for example 2-3 days or for as long as the shock condition arising from the antilymphocyte antibody therapy persists.
Where the anti-TNFα antibody is infused concurrently with an antilymphocyte antibody, the antilymphocyte antibody may be infused at generally accepted doses depending on the antibody in use, for example with Orthoclone OKT3 at a dose of 5 mg/day for 10-14 days in a 70 kg man.
In a further aspect of the invention we provide a method of treatment of a human subject suffering from an immunoregulatory disorder which comprises administering effective amounts of an anti-TNFα antibody and an antilymphocyte antibody in association to the human subject.
Immunoregulatory disorders include, for example, those described above.
In another aspect of the invention we provide a method of treatment of a human subject suffering from a shock condition arising from antilymphocyte antibody therapy which comprises administering an effective amount of an effective amount of an anti-TNFα antibody to the human subject.
DESCRIPTION OF SPECIFIC EMBODIMENTS Patients
Informed consent was obtained from seven consecutive kidney transplant patients, treated for acute allograft rejection with antithymocyte globulin (ATG) at the Maastricht University Hospital, to take serial blood samples for plasma tumour necrosis factor (TNF) measurement during ATG treatment. ATG treatment consisted of intravenous administration of 100-300 mg ATG together with 50 mg prednisolone in 500 ml saline, infused over a 8-hr period. All patients received 4 mg of the antihistamine chlorepheniraminemaleate orally 1/2 hr before start of the infusion. EDTA-anticoagulated 5 ml blood samples were drawn from an intravenous line inserted in the arm opposite the one in which ATG was infused. Blood samples were immediately centrifuged and aliquots of plasma were stored at -70° C. for measurement of TNF concentration. During treatment patient temperature and blood pressure were monitored and the occurrence of other side effects of the treatment was registered.
Enzyme-linked Immunosorbent Assay (ELISA) for TNF
Plasma TNF concentrations were determined with a TNF-specific ELISA using monoclonal and polyclonal anti-TNF antibodies. Monoclonal antibodies were derived from anti-TNF secreting hybridomas obtained by a standard cell fusion procedure. Two different monoclonal antibodies were coated overnight at 4° C. in a flatbottom microtiter plate (Greiner, Nurtingen, FRG) at a final concentration of 5 ug Ig/ml. Plates were blocked with 1% (w/v) bovine serum albumin. Samples to be tested for TNF concentration were added to the wells and incubated for 11/2 hrs. at room temperature. A standard titration curve was obtained by making serial dilutions of a known sample of recombinant TNF. The amount of TNF bound to the wells was quantitated by sequential incubation with a 1:2000 dilution of rabbit immune serum and a 1:5000 dilution of peroxidase conjugated goat anti-rabbit antibody (Jackson, West Grove, PA; antibody not crossreactive with human serum proteins), followed by adding substrate (o-phenylenediamine: Sigma, St. Louis, MO) to the wells. The colour reaction was stopped with 0.1M H2 SO4 and absorption of light at 495 nm was measured with a microelisa autoreader (Flow, Irvine, UK). The lower detection limit of ELISA ranged between 5-10 pg/ml in plasma. TNF specific values were obtained by subtracting background absorptions due to non-TNF plasma proteins cross-linking in the ELISA, measured in the absence of either the monoclonal anti-TNF antibodies coated on the bottom of the ELISA plate or the second, rabbit anti-TNF antibodies. Plasma samples of a large group (n=60) of healthy volunteers were shown to be negative for TNF (i.e.<5 pg/ml) as determined with our assay.
In vitro Experiments
Peripheral blood mononuclear cells (PBMC) were prepared by buoyant density centrifugation on Lymphoprep (Nyegaard, Oslo, Norway) of buffy coats of donor blood. Monocytes were obtained by depleting PBMC of T-lymphocytes through rosetting with sheep red blood cells and centrifugation on Lymphoprep after which the interface layer cells were left to adhere to plastic for 1/2 hr at 37° C. After extensive washing, to remove non-adherent cells, the cells were shown to consist of more than 95% of esterase-positive cells. PBMC and monocytes were cultured in RPMI 1640 (Gibco, Paisley, Scotland) supplemented with 10% heat-inactivated (56° C., 20 min.) foetal calf serum (Boehringer, Mannheim, FRG) and 100 IU/ml penicillin and 100 ug/ml streptomycin (Flow, Irvine, UK). PBMC and monocytes were cultured in cluster wells (24-well plates, Greiner); In each well 2.5×108 PBMC and monocytes obtained after adherence of 2.5×108 T lymphocyte depleted PBMC per well were cultured in 600 ul medium. To these cultures different concentrations of ATG and of the anti-CD3 monoclonal antibody OKT3 (ascites derived from an OKT3-secreting hybridoma, purchased from the ATCC, Rockville, MD) were added and at different times samples of cell-free supernatant were harvested to measure TNF concentration. Lymphocyte proliferation was determined by measuring the incorporation of 3 H-thymidine. 0.5 μCi 3 H-thymidine (Amersham, UK; specific activity 5.0 Ci/mmol) was added to a sample of 100 μl of the cell cultures transferred into round-bottomed microtiter plates (Greiner) and after a 4 hour culture period the radioactivity incorporated in the cells was measured with a liquid scintillation counter.
TNF Levels in patients treated with ATG
All 7 patients treated for kidney graft rejection with ATG showed elevated plasma TNF levels, starting about 1 hour and reaching peak levels between 2-3 hrs after the start of the ATG infusion. Plasma TNF returned to zero level at about 6 hrs after the beginning of therapy. All patients developed a rise in body temperature shortly after plasma TNF had reached peak values. Body temperature normalized on the average 6 hr after TNF disappeared from the circulation. In most of the patients a slight rise in blood pressure accompanied with an increased heart rate was observed during the ATG infusion. All patients experienced mild to severe side effects, which coincided in time with the period of elevated plasma TNF levels, and which made it necessary to temporarily discontinue the ATG-infusion in several patients. In all patients symptoms waned shortly after TNF plasma levels has returned to normal. All patients experienced a feeling of great fatigue at the end of the therapy. Table I gives the relevant data on all 7 patients. Maxium plasma TNF concentrations in these patients ranged between 111 and 731 pg/ml on the first day of treatment. On the second day of treatment, when side effects of the ATG infusion were considerably less, maximum TNF levels were much lower, i.e. between 0 and 55 pg/ml.
TNF-production by peripheral blood mononuclear cells in vitro
In vitro experiments were performed in order to elucidate the cell source and mechanism of production of TNF in these patients. ATG or OKT3 was added at different concentrations to cultures of peripheral blood mononuclear cells (PBMC) and after a 6 hour culture period, TNF concentration in the supernatant was determined. Both ATG and OKT3 induced in a dose-related manner the release of TNF by PBMC in vitro. OKT3, which is a T-cell mitogen, also induced T-lymphocyte proliferation. However, ATG induced TNF secretion was not accompanied by T-lymphocyte proliferation, indicating that proliferation of T-lymphocytes is not a necessary prerequisite for TNF production in these cultures.
The kinetics of the ATG- and OKT3-induced release of TNF by PBMC was compatible with the rapid release of TNF in the circulation of the ATG-treated patients.
                                  TABLE 1                                 
__________________________________________________________________________
Plasma TNF Concentrations And Other Relevant Data of ATG-treated          
Patients                                                                  
                 highest                                                  
     treatment   TNF conc.                                                
                       highest                                            
                             RR**                                         
Patient*                                                                  
     day  treatment                                                       
                 (pg/ml)                                                  
                       temp (°C.)                                  
                             (mm Hg)                                      
                                   symptoms                               
__________________________________________________________________________
1 m 33 yr                                                                 
     1    300 mg ATG                                                      
                 560   39.4  +50/+5                                       
                                   chills,                                
                                   vomiting                               
     2    200 mg ATG                                                      
                  55   37.9  0/0   none                                   
2 f 54 yr                                                                 
     1    100 mg ATG                                                      
                 179   39.5  +10/0 chills,                                
                                   dyspnoea                               
3 f 35 yr                                                                 
     1    200 mg ATG                                                      
                 111   39.0  +5/+5 chills                                 
     2    200 mg ATG                                                      
                  24   38.0  0/0   none                                   
4 m 49 yr                                                                 
     1    200 mg ATG                                                      
                 125   38.4  -30/-20                                      
                                   chills,                                
                                   dyspnoea,                              
                                   vomiting                               
     2    200 mg ATG                                                      
                  11   37.2  0/0   none                                   
5 f 61 yr                                                                 
     1    200 mg ATG                                                      
                 138   38.2  +15/0 none                                   
6 f 54 yr                                                                 
     1    200 mg ATG                                                      
                 731   40.4  +10/-10                                      
                                   chills,                                
                                   dyspnoea,                              
                                   headache                               
     2    100 mg ATG                                                      
                  0    37.4  0/0   none                                   
7 m 43 yr                                                                 
     1    200 mg ATG                                                      
                 593   39.5  +15/-10                                      
                                   chills,                                
                                   diarrhea,                              
                                   headache                               
__________________________________________________________________________
 *m = male; f = female                                                    
 **Expressed as difference between systolic/diastolic blood pressure      
 measured before start of the ATG infusion and at the time of the highest 
 plasma TNF concentration

Claims (8)

I claim:
1. A pharmaceutical composition which comprises an antibody against human α-tumour necrosis and an antilymphocyte antibody in admixture with one or more pharmaceutically acceptable carriers, excipients or diluents.
2. A pharmaceutical composition according to claim 1 wherein the antilymphocyte antibody is a monoclonal antilymphocyte antibody.
3. A pharmaceutical composition according to claim 2 wherein the monoclonal antilymphocyte antibody is Orthoclone OKT3™.
4. A two component system, each component for use in association with one another in antilymphocyte antibody therapy, said system comprising (1) a first component that is an antinbody against human α-tumour necrosis factor, and (2) a second component that is an antilymphocyte antibody.
5. A method of treatment of a human subject suffering from an immunoregulatory disorder amenable to treatment by antilymphocyte antibody therapy which comprises administering to said human subject an effective amount of an anti-TNFα antibody in association with an antilymphocyte antibody.
6. A pharmaceutical composition according to any one of claims 1 to 3 wherein the antibody against human α tumor necrosis factor is recombinant α tumor necrosis factor.
7. A method of treatment of a human subject suffering from a shock condition arising from antilymphocyte antibody therapy which comprises administering an effective amount of an antibody against human α-tumor necrosis factor to the human subject.
8. A method for the prevention or treatment of shock-related conditions arising from antilymphocyte antibody therapy comprising administering to a person in need of same an effective amount of an antibody against human α-tumor necrosis factor.
US07/881,317 1988-03-11 1989-03-13 Antibodies for use in antilymphocyte antibody therapy Expired - Fee Related US5183657A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US07/881,317 US5183657A (en) 1988-03-11 1989-03-13 Antibodies for use in antilymphocyte antibody therapy

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8805792 1988-03-11
GB888805792A GB8805792D0 (en) 1988-03-11 1988-03-11 Medicaments
US07/881,317 US5183657A (en) 1988-03-11 1989-03-13 Antibodies for use in antilymphocyte antibody therapy
US58506590A 1990-10-22 1990-10-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US58506590A Continuation 1988-03-11 1990-10-22

Publications (1)

Publication Number Publication Date
US5183657A true US5183657A (en) 1993-02-02

Family

ID=27263820

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/881,317 Expired - Fee Related US5183657A (en) 1988-03-11 1989-03-13 Antibodies for use in antilymphocyte antibody therapy

Country Status (1)

Country Link
US (1) US5183657A (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022790A1 (en) * 1995-01-23 1996-08-01 Xenotech Incorporated Composition to ameliorate osteolysis and metastasis
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6193969B1 (en) * 1993-06-03 2001-02-27 Protherics Inc. Antibody fragments in therapy
US6235281B1 (en) * 1994-02-07 2001-05-22 Knoll Aktiengesellschaft Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6
US6241985B1 (en) 1996-05-15 2001-06-05 Altarex Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US20030135029A1 (en) * 1992-02-18 2003-07-17 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
WO2003026692A3 (en) * 2001-09-26 2003-12-18 Isis Innovation Treatment of chronic joint inflammation using an antibody against the cd3 antigen complex
US20040131612A1 (en) * 2003-01-08 2004-07-08 Watkins Jeffry D. TNF-alpha binding molecules
US20040131609A1 (en) * 2000-01-27 2004-07-08 Young James F. Ultra high affinity neutralizing antibodies
US20050031619A1 (en) * 2001-03-21 2005-02-10 Nicodemus Christopher F. Therapeutic compositions that alter the immune response
US20050049402A1 (en) * 2002-12-02 2005-03-03 Babcook John S. Antibodies directed to tumor necrosis factor and uses thereof
US20050063976A1 (en) * 1996-05-15 2005-03-24 Altarex --Medical-- Corp. Combination therapy for treating disease
US20050220789A1 (en) * 1997-08-29 2005-10-06 The Brigham And Women's Hospital Inc. Novel T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060269549A1 (en) * 2004-01-08 2006-11-30 Watkins Jeffry D Tnf-alpha binding molecules
US20070092522A1 (en) * 1998-03-20 2007-04-26 Altarex Medical Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US20090104205A1 (en) * 1994-08-15 2009-04-23 Medimmune, Llc Human-Murine Chimeric Antibodies Against Respiratory Syncytial Virus
US7605233B2 (en) 1989-08-07 2009-10-20 Arana Therapeutics Limited Tumour necrosis factor binding ligands
US20090291075A1 (en) * 2002-04-11 2009-11-26 Altarex Medical Corp. Binding agents and their use in targeting tumor cells
US7635568B2 (en) 2000-11-28 2009-12-22 Medimmune, Llc Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US20100028948A1 (en) * 2000-11-28 2010-02-04 Medimmune, Llc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
US7700735B2 (en) 2000-03-01 2010-04-20 Medimmune, Llc High potency recombinant antibodies and method for producing them
US7785592B2 (en) 2002-06-14 2010-08-31 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US20100239593A1 (en) * 2007-06-01 2010-09-23 Medimmune Limited Rsv-specific binding molecules and means for producing them
US20100291103A1 (en) * 2007-06-06 2010-11-18 Domantis Limited Polypeptides, antibody variable domains and antagonists
US20110158985A1 (en) * 2004-10-29 2011-06-30 Medimmune, Llc Methods of preventing and treating rsv infections and related conditions
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0218868A2 (en) * 1985-08-29 1987-04-22 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0218868A2 (en) * 1985-08-29 1987-04-22 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, abstract 154301t, vol. 106, 1987. *
Debets et al Transplantation, vol. 47, No. 3 pp. 487 492, Mar. 1989. *
Debets et al Transplantation, vol. 47, No. 3 pp. 487-492, Mar. 1989.
Robinson, Muromonab CD3 (Orthoclone OKT3 ) A Review, Drugs of Today, pp. 603 609, vol. 22, No. 12, 1986. *
Robinson, Muromonab-CD3 (Orthoclone OKT3®)-A Review, Drugs of Today, pp. 603-609, vol. 22, No. 12, 1986.
Tracey et al Nature, vol. 330 Dec. 17, 1987 pp. 662 664. *
Tracey et al Nature, vol. 330 Dec. 17, 1987 pp. 662-664.

Cited By (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162948A1 (en) * 1989-08-07 2003-08-28 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US20060140951A1 (en) * 1989-08-07 2006-06-29 Rathjen Deborah A Tumour necrosis factor binding ligands
US7517963B2 (en) 1989-08-07 2009-04-14 Arana Therapeutics Limited Tumour necrosis factor binding ligands
US20060233802A1 (en) * 1989-08-07 2006-10-19 Peptech Limited Tumour necrosis factor binding ligands
US20060204499A1 (en) * 1989-08-07 2006-09-14 Peptech Limited Tumour necrosis factor binding ligands
US20030216552A1 (en) * 1989-08-07 2003-11-20 Rathjen Deborah Ann Tumour necrosis factor peptide binding antibodies
US20060182746A1 (en) * 1989-08-07 2006-08-17 Rathjen Deborah A Tumour necrosis factor binding ligands
US7605233B2 (en) 1989-08-07 2009-10-20 Arana Therapeutics Limited Tumour necrosis factor binding ligands
US7553641B2 (en) 1989-08-07 2009-06-30 Arana Therapeutics Limited Tumour necrosis factor binding ligands
US7528237B2 (en) 1989-08-07 2009-05-05 Arana Therapeutics Limited Tumour necrosis factor binding ligands
US20070077248A1 (en) * 1989-08-07 2007-04-05 Peptech Limited Tumour necrosis factor binding ligands
US7544782B2 (en) 1989-08-07 2009-06-09 Arana Therapeutics Limited Tumour necrosis factor binding ligands
US20060159677A1 (en) * 1989-08-07 2006-07-20 Peptech Limited Tumour necrosis factor peptide binding antibodies
US20070287177A1 (en) * 1989-08-07 2007-12-13 Rathjen Deborah A Tumour necrosis factor binding ligands
US20040002589A1 (en) * 1989-08-07 2004-01-01 Rathjen Deborah Ann Tumour necrosis factor peptide binding antibodies
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US20030166874A1 (en) * 1989-08-07 2003-09-04 Rathjen Deborah Ann Tumour necrosis factor peptide binding antibodies
US20040002590A1 (en) * 1989-08-07 2004-01-01 Rathjen Deborah Ann Tumour necrosis factor peptide binding antibodies
US20030171554A1 (en) * 1989-08-07 2003-09-11 Rathjen Deborah Ann Tumour necrosis factor peptide binding antibodies
US20030171553A1 (en) * 1989-08-07 2003-09-11 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US20030208047A1 (en) * 1989-08-07 2003-11-06 Rathjen Deborah Ann Tumour necrosis factor peptide binding antibodies
US20030232970A1 (en) * 1989-08-07 2003-12-18 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US20030139580A1 (en) * 1992-02-18 2003-07-24 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US20030135029A1 (en) * 1992-02-18 2003-07-17 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US20030208049A1 (en) * 1992-02-18 2003-11-06 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US20030170204A1 (en) * 1992-02-18 2003-09-11 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US20030139577A1 (en) * 1992-02-18 2003-07-24 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US20040214993A2 (en) * 1992-02-18 2004-10-28 Deborah Rathjen Tumour necrosis factor binding ligands
US6193969B1 (en) * 1993-06-03 2001-02-27 Protherics Inc. Antibody fragments in therapy
US6235281B1 (en) * 1994-02-07 2001-05-22 Knoll Aktiengesellschaft Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6
US20090104205A1 (en) * 1994-08-15 2009-04-23 Medimmune, Llc Human-Murine Chimeric Antibodies Against Respiratory Syncytial Virus
US7704505B2 (en) 1994-08-15 2010-04-27 Medimmune, Llc Human-murine chimeric antibodies against respiratory syncytial virus
US8562994B2 (en) 1994-08-15 2013-10-22 Medimmune, Llc Human-murine chimeric antibodies against respiratory syncytial virus
WO1996022790A1 (en) * 1995-01-23 1996-08-01 Xenotech Incorporated Composition to ameliorate osteolysis and metastasis
AU703222B2 (en) * 1995-01-23 1999-03-18 Xenotech Incorporated Composition to ameliorate osteolysis and metastasis
US20050244414A1 (en) * 1995-01-23 2005-11-03 Xenotech Incorporated Method to ameliorate osteolysis and metastasis
US5955364A (en) * 1995-06-07 1999-09-21 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US5939068A (en) * 1995-06-07 1999-08-17 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US5866125A (en) * 1995-06-07 1999-02-02 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US5840298A (en) * 1995-06-07 1998-11-24 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US6241985B1 (en) 1996-05-15 2001-06-05 Altarex Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US20050063976A1 (en) * 1996-05-15 2005-03-24 Altarex --Medical-- Corp. Combination therapy for treating disease
US20070036798A1 (en) * 1996-05-15 2007-02-15 Altarex Medical Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US20010036457A1 (en) * 1996-05-15 2001-11-01 Ragupathy Madiyalakan Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US20080311127A1 (en) * 1996-05-15 2008-12-18 Altarex Medical Corp. Combination therapy for treating disease
US7863418B2 (en) 1997-08-29 2011-01-04 The Brigham And Women's Hospital, Inc. T-cell membrane protein (TIRC7) and peptides derived therefrom
US20050220789A1 (en) * 1997-08-29 2005-10-06 The Brigham And Women's Hospital Inc. Novel T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof
US20070092522A1 (en) * 1998-03-20 2007-04-26 Altarex Medical Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US20090202560A1 (en) * 1998-03-20 2009-08-13 Altarex Medical Corp. Method for diagnosing efficacy of xenotypic antibody therapy
US7740851B2 (en) 2000-01-27 2010-06-22 Medimmune, Llc Ultra high affinity neutralizing antibodies
US20040131609A1 (en) * 2000-01-27 2004-07-08 Young James F. Ultra high affinity neutralizing antibodies
US8153133B2 (en) 2000-03-01 2012-04-10 Medimmune, Llc High potency recombinant antibodies and method for producing them
US7700735B2 (en) 2000-03-01 2010-04-20 Medimmune, Llc High potency recombinant antibodies and method for producing them
US20100239574A1 (en) * 2000-03-01 2010-09-23 Medimmune, Llc High potency recombinant antibodies and method for producing them
US7635568B2 (en) 2000-11-28 2009-12-22 Medimmune, Llc Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7847082B2 (en) 2000-11-28 2010-12-07 Medimmune, Llc Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US20100028948A1 (en) * 2000-11-28 2010-02-04 Medimmune, Llc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
US20050031619A1 (en) * 2001-03-21 2005-02-10 Nicodemus Christopher F. Therapeutic compositions that alter the immune response
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20050037004A1 (en) * 2001-09-26 2005-02-17 Isis Innovation Limited Treatment of chronic joint inflammation
AU2008207338B2 (en) * 2001-09-26 2011-12-08 Oxford University Innovation Limited Treatment of chronic joint inflammation using an antibody against the CD3 antigen complex
EP2199307A1 (en) 2001-09-26 2010-06-23 Isis Innovation Ltd Treatment of chronic joint inflammation using an antibody against the cd3 antigen complex
EP1803466A1 (en) * 2001-09-26 2007-07-04 Isis Innovation Limited Treatment of chronic joint inflammation by an anti-CD3 antibody
WO2003026692A3 (en) * 2001-09-26 2003-12-18 Isis Innovation Treatment of chronic joint inflammation using an antibody against the cd3 antigen complex
US20090291075A1 (en) * 2002-04-11 2009-11-26 Altarex Medical Corp. Binding agents and their use in targeting tumor cells
US8206951B2 (en) 2002-06-14 2012-06-26 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US11180542B2 (en) 2002-06-14 2021-11-23 Arexis Ab Stabilized liquid anti-RSV antibody formulations
US10604560B2 (en) 2002-06-14 2020-03-31 Arexis Ab Stabilized liquid anti-RSV antibody formulations
US9879067B2 (en) 2002-06-14 2018-01-30 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US9272032B2 (en) 2002-06-14 2016-03-01 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US8986686B2 (en) 2002-06-14 2015-03-24 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US7785592B2 (en) 2002-06-14 2010-08-31 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US8007793B2 (en) 2002-06-14 2011-08-30 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US8460663B2 (en) 2002-06-14 2013-06-11 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US20080187531A1 (en) * 2002-12-02 2008-08-07 Babcook John S Antibodies directed to tumor necrosis factor and uses thereof
US8101178B2 (en) 2002-12-02 2012-01-24 Amgen Fremont Inc. Antibodies directed to tumor necrosis factor and uses thereof
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
US20050049402A1 (en) * 2002-12-02 2005-03-03 Babcook John S. Antibodies directed to tumor necrosis factor and uses thereof
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US20040131612A1 (en) * 2003-01-08 2004-07-08 Watkins Jeffry D. TNF-alpha binding molecules
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
US20060269549A1 (en) * 2004-01-08 2006-11-30 Watkins Jeffry D Tnf-alpha binding molecules
US20110158985A1 (en) * 2004-10-29 2011-06-30 Medimmune, Llc Methods of preventing and treating rsv infections and related conditions
US9321831B2 (en) 2007-06-01 2016-04-26 Medimmune Limited RSV-specific binding molecules and means for producing them
US10059757B2 (en) 2007-06-01 2018-08-28 Medimmune Limited RSV-specific binding molecules and means for producing them
US20100239593A1 (en) * 2007-06-01 2010-09-23 Medimmune Limited Rsv-specific binding molecules and means for producing them
US10730931B2 (en) 2007-06-01 2020-08-04 Medimmune Limited RSV-specific binding molecules and means for producing them
US8562996B2 (en) 2007-06-01 2013-10-22 Medimmune Limited RSV-specific binding molecules and means for producing them
US8877186B2 (en) 2007-06-06 2014-11-04 Domantis Limited Polypeptides, antibody variable domains and antagonists
US20100291103A1 (en) * 2007-06-06 2010-11-18 Domantis Limited Polypeptides, antibody variable domains and antagonists
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
US9283274B2 (en) 2009-10-06 2016-03-15 Medimmune Limited RSV specific binding molecule
US10035843B2 (en) 2009-10-06 2018-07-31 Medimmune Limited RSV-specific binding molecule
US10723786B2 (en) 2009-10-06 2020-07-28 Medimmune, Limited RSV-specific binding molecule

Similar Documents

Publication Publication Date Title
US5183657A (en) Antibodies for use in antilymphocyte antibody therapy
EP0403558B1 (en) Antibodies for use in antilymphocyte antibody therapy
Hooks et al. Muromonab CD‐3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation
US6338848B1 (en) Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
US5980892A (en) Monoclonal antibodies reactive with defined regions of the T cell antigen receptor
US6333032B1 (en) Treatment of autoimmune diseases
JP3383303B2 (en) CDw52-specific antibodies for the treatment of multiple sclerosis
EP0625912B1 (en) Treatment for inflammatory bowel disease
JP5027512B2 (en) Immunomodulation
US8012475B2 (en) Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
Combe et al. Human placenta-eluted gammaglobulins in immunomodulating treatment of rheumatoid arthritis
MXPA01010985A (en) Method and compositions for preventing or reducing hiv infection by use of inhibitors for leucine aminopeptidase.
EP0397764A1 (en) Method of reducing immunoglobulin e responses
CA2563260C (en) Methods of treating autoimmune and inflammatory diseases
Shoda et al. Cutaneous vasculitis developed in a patient with breast cancer undergoing aromatase inhibitor treatment
US20030059428A1 (en) Treatment of autoimmune diseases
US5874228A (en) Methods and kits for determining the levels of IGE-BF
Larue et al. Optimization of mouse IgG fragmentation technique in the selection of monoclonal antibodies for myocardial infarct imaging
Tanimoto (3) Lymphocyte Function in autoimmune Disease
HK1099525B (en) Methods of treating atherosclerosis
HK1007683B (en) Treatment for inflammatory bowel disease
HK1098085B (en) Methods of modulating immunity
AU1247300A (en) Methods for the treatment of inflammatory joint disease

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20050202